和铂医药-B(02142)与 AstraZeneca修订合作协议 合作范围进一步扩展

Core Viewpoint - The collaboration between 和铂医药-B and AstraZeneca aims to leverage both companies' expertise to discover and develop next-generation biotherapies, including antibody-drug conjugates (ADCs) and T-cell engagers, under a revised agreement set to take effect on November 24, 2025 [1] Group 1 - 和铂医药-B's indirect wholly-owned subsidiary, 和铂医药(上海)有限责任公司, has entered into a collaboration, option, and licensing agreement with AstraZeneca PLC [1] - The scope of collaboration has been further expanded following the revision of the agreement between 和铂上海 and AstraZeneca [1] - The economic terms and financial framework established under the collaboration agreement remain consistent [1]